anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Digital health interventions (DHIs) have shown promising results for the management of chronic wounds. However, its effectiveness compared to usual care and whether variability in the type of intervention affects wound outcomes are unclear.
OBJECTIVE: The main objective was to determine the effectiveness of DHIs on wound healing outcomes in adult patients with chronic wounds. The secondary objectives were to assess if there was any variation in wound healing outcomes across the various types of DHIs.
METHODS: In total, 9 databases were searched for the literature up to August 1, 2023. Randomized controlled trials (RCTs), cohort studies, and quasi-experimental studies comparing the efficacy of DHIs with controls in improving wound outcomes in adult patients with chronic wounds were included. Study selection, data extraction, and risk of bias assessment were conducted independently by 2 reviewers. We assessed the quality of each RCT, cohort study, and quasi-experimental study separately using the Cochrane risk of bias tool, ROBINS-I, and the Joanna Briggs Institute Critical Appraisal tools checklists. Relative risks (RRs) and 95% CIs were pooled using the random effects model, and heterogeneity was assessed by the I2 statistic. Subgroup analysis and sensitivity analysis were also performed.
RESULTS: A total of 25 studies with 8125 patients were included in this systematic review, while only 20 studies with 6535 patients were included in the meta-analysis. Efficacy outcomes in RCTs showed no significant differences between the DHIs and control groups in terms of wound healing (RR 1.02, 95% CI 0.93-1.12; P=.67) and all-cause mortality around 1 year (RR 1.08, 95% CI 0.55-2.12; P=.83). Compared with the control group, the use of DHIs was associated with significant changes in adverse events (RR 0.44, 95% CI 0.22-0.89; P=.02). Subgroup analysis suggested a positive effect of the digital platforms in improving wound healing (RR 2.19, 95% CI 1.35-3.56; P=.002). Although meta-analysis was not possible in terms of wound size, cost analysis, patient satisfaction, and wound reporting rates, most studies still demonstrated that DHIs were not inferior to usual care in managing chronic wounds.
CONCLUSIONS: The findings of our study demonstrate the viability of adopting DHIs to manage chronic wounds. However, more prominent, high-quality RCTs are needed to strengthen the evidence, and more detailed clinical efficacy research is required.
TRIAL REGISTRATION: PROSPERO CRD42023392415; https://tinyurl.com/4ybz6bs9.
This study adopts a prospective research design, with 60 patients suspected of having liver mass undergoing 18F-FDG PET/enhanced MR examination over one year. The inclusion criteria are as follows: age ≥ 18 years old; Patients suspected of having liver metastasis or liver lesions, based on clinical symptoms and laboratory tests (such as alpha-fetoprotein level); Preliminary findings from other routine imaging examinations; Able to perform 18F-FDG PET/MR examination and agree to follow the research procedure. The exclusion criteria are as follows: patients with a history of allergy to MR contrast agents; Pregnant or lactating women; Patients with severe heart disease, renal failure, liver failure, etc; Patients who are unable to cooperate in completing PET/MR examinations. This study passed the ethical review of Shanghai Oriental Hospital, and patients signed informed consent forms after enrollment.
<P>PROBLEM TO BE SOLVED: To provide a technique for complementing skin barrier function lowered by irradiation, etc., of ultraviolet light.  <P>SOLUTION: The external preparation for skin comprises (1) an N-acylglutamic acid diester and (2) a pyrrolidonecarboxylic acid-modified dimethylpolysiloxane. The external preparation for skin has, preferably, a phytosterol residue as a group constituting the ester part of the N-acylglutamic acid diester and the external preparation comprises, preferably further, hyaluronic acid and/or its salt. The external preparation is preferably a cosmetic for summer. The cosmetic has action for complementing a skin barrier function lowered by ultraviolet light.  <P>COPYRIGHT: (C)2007,JPO&INPIT
INTRODUCTION AND OBJECTIVE: To report our initial experience with enhanced MOSES 2.0 technology in patients who underwent holmium laser enucleation of the prostate (HoLEP) for the treatment of benign prostatic hyperplasia (BPH), in comparison to those who underwent HoLEP with MOSES 1.0 technology at our institution.
METHODS: We retrospectively reviewed data of patients who underwent HoLEP using MOSES 1.0 or MOSES 2.0 pulse-modulation technology from December 2020 to September 2023. Preoperative and intraoperative parameters, postoperative outcomes, as well as perioperative complications were collected and analyzed.
RESULTS: A total of 196 patients were included in the study. Among them, 146 patients underwent MOSES 1.0 HoLEP, while 50 had MOSES 2.0 HoLEP. No statistically significant differences in preoperative characteristics were observed between the two groups. The median prostate volume for the MOSES 1.0 and MOSES 2.0 HoLEP groups was 109 cc and 117.5 cc, respectively. Patients in the MOSES 2.0 group had a shorter median enucleation time (52.5 vs. 42.5 min, p < 0.001) and hemostasis time (8 vs. 6 min, p = 0.002), along with lower laser energy usage (101 vs. 86.4 kJ, p = 0.012), when compared to those in the MOSES 1.0 cohort. Postoperative outcomes, including IPSS, QoL, Qmax, and PVR, were comparable between the two groups at 1, 3, and 6 months postoperative. The incidence of hospital readmission (p = 0.42), as well as one-month postoperative urge urinary incontinence (p = 0.2) and stress urinary incontinence (p = 0.13) were also comparable between the cohorts.
CONCLUSIONS: HoLEP with second-generation MOSES 2.0 technology is a safe and effective treatment option for BPH. It offers notable improvements, including reduced enucleation and hemostasis times, while using less energy when compared to MOSES 1.0.
An ultraviolet protection composition is provided to have a excellent transmittance of a visible ray and an excellent stability, to block an ultraviolet ray between 200 and 400 nm, to maintain an initial luminance property of a fluorescent light source and to prevent a degeneration of product economically. An ultraviolet protection composition comprises a) a 0.1 - 60 weight% of composite containing a zinc oxide and a metal oxide having yellow and b) a remained solvent for dilution. A mixing mole rate of the metal oxide and the zinc oxide is 50 - 99 : 1 - 50. The metal oxide having yellow is selected from indium(In), bismuth(Bi), vanadium(V) and tungsten(W). A maximum diameter of the composite is 1000 nm or less and an average diameter of the composite is 10 - 200 nm. The ultraviolet protection composition additionally comprises a binder or a dispersing agent.
Dyspnea is "a subjective experience of breathing discomfort that consists of qualitatively distinct sensations that vary in intensity." Dyspnea, or shortness of breath, is a common problem affecting up to half of hospitalized patients; and "shortness of breath" and "labored or difficult breathing" accounts for 3 to 4 million emergency department visits annually. Dyspnea can represent a sensation, a symptom, or an illness. Each set of experiences involves distinct sensory, perceptual, and cognitive processes, including: the detection of signals; the perception of threat or remarkable challenge; and, the construction, or mental representation, of illness. As a sensory experience dyspnea can be compared to the sensation of pain. Although labored breathing is not painful in the usual sense of the word dyspnea, like pain, is a concept varying along multiple dimensions. Like pain, dyspnea can signal the need for medical attention; but unlike pain dyspnea is a localized sensation originating in the cardiopulmonary system rather than a generalized danger signal.

Research demonstrates that sensory information from the respiratory system activates regions of the cerebral cortex to produce the perception of dyspnea but far less is known about the neurophysiology of dyspnea than about vision, hearing, or even pain. Dyspnea likely arises from multiple nervous system sources. Investigations of the mechanisms underlying respiratory sensations have included studies of airway anesthesia, chest wall strapping, exercise, heart-lung transplantation, hyperventilation, and opioid use. Study of the perception of breathing sensations in individuals with a spinal cord injury presents additional opportunity. The goal of the proposed project is to examine the effects of increasingly severe levels of spinal cord injury on the perception of breathing sensations in participants who are able to breathe without the use of a ventilator.

Afferent pathways that transmit somatosensory signals to the central nervous system (i.e., brain and spinal cord) are well described and event-related potentials have been used to measure respiratory somatosensation with high temporal resolution. Event-related potentials (ERPs) are time-locked cortical signals that are measured non-invasively from the surface of the scalp in response to brief (\< 200 msec), presentations of respiratory stimuli during normal breathing. Davenport et al. first identified sensory-perceptual ERPs to inspiratory stimuli (those occurring about 50-150 msec after stimulus delivery) and Harver et al. first examined perceptual-cognitive ERPs to inspiratory stimuli (those occurring about 150-400 msec post-stimulus). Study of respiratory-related ERPs in patients with spinal cord injuries presents a rare opportunity to examine the neurophysiological mechanisms underlying the perception of breathing because the extent of somatosensory information that reaches cerebral cortex varies with level of lesion.
A tri-color or alternating bi-color lipstick and method of molding the same is disclosed. The lipstick is formed using a known book-type mold. The color divisions are achieved by using a removable insert. One insert is used to form the middle section. Another insert is a solid plate and is used to prevent lipstick product from entering the middle section while the outer sections are being filled. In use, the lipstick is axially rotated by the user to present the desired color to the lips. In serial or simultaneous fashion, more than one color may be applied to permit blending.
The early years between ages 3-7 are critical in the development of obesity. The importance of the family in the development of children's eating and activity behaviors has been emphasized by experts, yet to date no obesity prevention interventions incorporating a strong family focus with emphasis on improved parenting practices have been developed. The work proposed here will address this gap by testing the efficacy of an 8-mo parenting intervention designed to change both social and physical aspects of the home environment, which in turn will reduced % body fat in children. Subjects will be 280 families (one parent and one child from each) with at least one preschool-age child (2-5 years old). Following baseline measures, pairs will be randomized into intervention or control. The intervention will teach more effective parenting skills (child management, communication, routines, etc.), then apply these skills to specific practices that encourage healthier behaviors. The intervention will include group sessions and tailored phone calls facilitated by a registered dietitian who has also received training in parent education. Group sessions will use multiple teaching strategies and include separate child activities. Tailored calls will use motivational interviewing techniques to help parents overcome barriers to behavior change. The intervention is guided by Darling and Steinberg's Integrative Model of parenting, which highlights the importance of parenting values, style and practices in child socialization, and Deci and Ryan's Self-Determination Theory, which suggests ways to foster autonomous motivation to adopt new behaviors. The resulting intervention will help parents learn skills to reduce their parenting-related stress and create home environments that support healthy-weight behaviors. The primary outcome, % body fat in children, will be assessed using anthropometry and a validated prediction equation (Dezenberg, 1999). Analyses will include baseline measurements of the outcome as a covariate. Secondary measures include child and parent diet and physical activity, parenting style and practices, and home environment. Maintenance effect will be assessed following a 6-mo no-intervention period. A comprehensive analysis is included to test for mediation effects. This intensive intervention will create the exposure necessary to make life-altering changes in weight-related behaviors. Plans build on extensive formative work conducted by our experienced researchers.
In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 450 mg + RZR 60 mg q.d. by mouth for 8 weeks.
The most commonly known form of exercise for Temporomandibular Disfunction is Rocabado exercises, which use 6 types of exercises 6 times a day. The purpose of Servical Core exercises is to support the vertebral column, especially by activating the stabilizing muscles, and to develop and maintain proper cervical posture by increasing kinesthetic awareness. At the beginning of the exercises, the patient is taught to contract the deep stabilizer muscles in a controlled manner, in isolation, without contraction of the superficial muscles. Exercises 2 days a week for 8 weeks, maximum 30 minutes. The session will be actively applied by the patient for a period of time.
A system can provide efficiency in monitoring prescription medication can include a client computer system configured to service a user interface (UI) for facilitating a pill counting procedure. The client receives a notification from a server computer system to initiate a pill count. The instructions can also cause the system to display a UI on the client computer system to facilitate the pill counting procedure. The displayed layout includes: (i) a timestamp field; (ii) a pill count field; (iii) an image field displaying an image of the pills the user has; (iv) a certification field; and (v) a submit field. On submission, the system can generate an encrypted data file comprising a secret key that de-identifies the user, the image of the pills, and metadata describing conditions associated with the pill count. The system can then transmit the encrypted data file to the server computer system.
The invention discloses a Huolong Dan, and belongs to the field of a high fever therapy of the traditional Chinese medical science. The Huolong Dan produces curative effects without causing a fever. The Huolong Dan is suitable for prevention and treatment on the Yang failure disease defined by the traditional Chinese medical science. The Huolong Dan has good effects of treating Yang failure and immunity decline caused by tumors, hepatitis B and leukemia. The Huolong Dan is widely suitable for prevention and treatment on multidisciplinary diseases such as stomach cold, lung cold-caused diseases, hand and foot cold, body cold, diuresis and deafness, and is a product for improving Yang qi and immunity. The Huolong Dan accords with a traditional Chinese medical science principle of diagnosis and treatment based on an overall analysis of the illness and the patient's condition, has a unique formula, obvious curative effects and strong and wide applicability, and is suitable for processing production.
One hundred and fifteen subjects were allocated into two large groups, V tecnique group and palpation tecnique group. Researchers will perform the V technique on the patient's inguinal area. This technique was performed using the researcher's contralateral hand. After the V technique is performed, the next researcher will perform the technique of palpating the femoral artery pulse at the exact location as the V technique. This technique is done by palpating the femoral artery pulsation using the examiner's index and middle fingers along the inguinal ligament; the location of the femoral vein is at 1 cm. medial to the femoral artery 2 cm inferior to the inguinal ligament. This location is marked "y" with a UV marker. researchers will compare the accuracy of both techniques in determining the exact location of femoral veins.
Total knee arthroplasty (TKA) is an effective treatment for patients with knee osteoarthritis (OA) accompanied by severe pain and functional limitations. With the success of this treatment and increasing incidence of OA, it has been projected that \~3.5 million older adults will undergo TKA annually by the year 2030. While TKA is effective for reducing pain and improving health-related quality of life, TKA patients experience significant skeletal muscle atrophy and weakness in the surgical leg following surgery which, long-term, can compromise balance, functional mobility and increase fall risk. Thus, interventions to mitigate muscle atrophy and weakness post-surgery are essential to improving long-term outcomes in patients undergoing TKA.

This randomized controlled trial will study the effects of peanut protein supplementation on changes in muscle size and quality in patients undergoing total knee arthroplasty. Patients (n=30) between the ages of 60-75 years scheduled to undergo total knee arthroplasty at the Jack Hughston clinic/hospital will be recruited to participate. Participants will be stratified by gender and randomized to a peanut protein (PP) supplementation (72g daily, n=15) or waitlist control (standard care with no PP, n=15) group who will be provided with PP following the intervention. Participants in the PP group will consume PP daily starting 7 days prior to surgery and for 6 weeks post-surgery. Participants will be monitored for changes in muscle size and quality (peripheral quantitative computed tomography), upper-leg strength (isokinetic dynamometry), knee range of motion (ROM; goniometry), pain (questionnaire and pressure algometry), and functional mobility outcomes (questionnaire, timed up and go, 2-min walk test) prior to surgery and at 6 and 12-weeks post-surgery.
The invention relates to a standardized plant extract from the biomass of in vitro cultures of Haberlea rhodopensis Friv. (HR) containing biologically active substances and their primary and secondary metabolites, containing in % by weight the following: organic acids from 4.0 to 6.0, fatty acids from 0.5 to 1.5, amino acids from 8.0 to 12.0, sterols from 0.5 to 1.0, free phenols from 3.0 to 6.0, sugars from 45 to 55 and polyphenols from 25.0 to 35.0 with a predominant myconoside content of 70% to 96% in the polyphenolic fraction, comprising from 18% to 35% in the total extract and to a composition containing the standardized extract and glycerol, as well as to a method for preparing the standardized extract thereof. The method, according to the present invention, with its optimally selected steps, specific conditions, parameters such as temperature, time, stirring, light, growth factors and the like achieves not only maximum volumetric productivity of the target substances and myconoside, but also stable productivity of in vitro cultures and is a reliable productive continuous 24/7 system for the production of HP. The dependence on natural factors, limited availability and protection of its rare wild plant populations have been eliminated. The limitations on the seasonality and slow growth of HR have also been avoided, and a renewable, environmentally friendly method has been developed. The developed method provides alternative, renewable and sustainable sources of plant raw materials needed to obtain the target extract. The obtained standardized extract of myconoside makes it especially valuable for its protective effect on human health, as well as its successful use with its pharmacological, cosmetic effects and in functional nutrition.
Mitochondrial oxidative phosphorylation (OXPHOS) fuels cellular ATP demands. OXPHOS defects lead to severe human disorders with unexplained tissue specific pathologies. Mitochondrial gene expression is essential for OXPHOS biogenesis since core subunits of the complexes are mitochondrial-encoded. COX14 is required for translation of COX1, the central mitochondrial-encoded subunit of complex IV. Here we describe a COX14 mutant mouse corresponding to a patient with complex IV deficiency. COX14M19I mice display broad tissue-specific pathologies. A hallmark phenotype is severe liver inflammation linked to release of mitochondrial RNA into the cytosol sensed by RIG-1 pathway. We find that mitochondrial RNA release is triggered by increased reactive oxygen species production in the deficiency of complex IV. Additionally, we describe a COA3Y72C mouse, affected in an assembly factor that cooperates with COX14 in early COX1 biogenesis, which displays a similar yet milder inflammatory phenotype. Our study provides insight into a link between defective mitochondrial gene expression and tissue-specific inflammation.
This group received a combination of Dexmedetomidine (1 ug/kg) and Fentanyl (1.79 ug/kg). Total number of patients in this group 24.
Women older than 18 years and with a benign endometrial disturbance will be included. Blood sampling will be performed on all subjects and will be used for proteomics and metabolomics analyses.
Pioglitazone 15 milligram (mg) and alogliptin 25 mg in fixed dose combination (FDC) tablet (SYR-322-4833), orally once daily and metformin greater than or equal to (\>=) 500 mg, tablet, orally, twice a day for up to 26 weeks. At Week 12, if participants has HbA1c \>=7.5%, pioglitazone dose will be titrated up to 30 mg based on investigator's opinion and up-titrated dose will be maintained up to Week 26.
From Days 1 to 8, participants will receive 600 mg RIF every 24 hours. From Days 9 to 19, participants will receive 300 mg ATV and 100 mg RTV every 12 hours and 600 mg RIF every 24 hours. From Days 20 to 27, participants will receive 400 mg ATV and 100 mg RTV every 12 hours and 600 mg RIF every 24 hours.
<P>PROBLEM TO BE SOLVED: To provide a base for external use, stable even when alcohol or the like is added thereto, having good sense of use, and containing a nonionic polymer having little interaction with principal agent as a main component.  <P>SOLUTION: The base for external use contains a cellulose ether with a low substitution degree, having 0.05-1.0 molar substitution degree with an alkyl group and/or a hydroxyalkyl group. The cellulose ether with the low substitution degree is homogeneously dispersed as particles in a swelled state. The method for producing the base for external use involves a step for swelling and dispersing the cellulose ether with the low substitution degree of 0.05-1.0 molar substitution degree in water by shearing and grinding. In another aspect, the method for producing the base for external use comprises a step for dissolving the cellulose ether with the low substitution degree of 0.05-1.0 molar substitution degree in an alkaline aqueous solution, and a step for shearing and grinding the obtained solution while or after neutralizing the solution by adding an acid.  <P>COPYRIGHT: (C)2003,JPO
After pre-testing, participants were randomly assigned to two groups. The participants of the TRT group were conducted in a 12-week (July 3 to September 22, 2023) traditional resistance training program that was performed one hour and three times per week (Mondays, Wednesdays, and Fridays from 4 to 5 pm) in the Ganzhou Shangyou base.